Bronchodilator Drugs - G20

The Bronchodilator Drugs market, a significant market in the pharmaceutical industry, is poised for substantial growth.
According to projections, the market is expected to generate a staggering revenue of US$29.97bn in 2024.
Over the following four years (2024-2029), the market is anticipated to exhibit a steady compound annual growth rate (CAGR) of 3.53%.
If this growth trajectory continues, the market volume is estimated to reach US$35.64bn by 2029.
When considering global comparisons, it is noteworthy that United States is expected to dominate the market, generating the highest revenue among all countries.
In 2024 alone, United States is projected to generate US$17,340.00m in revenue.
This highlights the country's significant role in the Bronchodilator Drugs market, especially within the context of the G20 nations.
In the bronchodilator drugs market, the G20 country of Brazil has seen a rising demand for inhalers due to high pollution levels.

Key regions: United States, Europe, Brazil, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Bronchodilator drugs are a type of medication that helps to relax the muscles in the airways, allowing individuals to breathe easier. The Bronchodilator Drugs market in G20 has been experiencing steady growth over the past few years.

Customer preferences: The increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) has been a major driver of the Bronchodilator Drugs market in G20. Additionally, the rising geriatric population in many countries has also contributed to the growth of the market.

Trends in the market: The Bronchodilator Drugs market in G20 has been characterized by the increasing use of combination therapies. These therapies involve the use of multiple bronchodilators to achieve better outcomes in patients with severe respiratory diseases. Additionally, there has been a growing trend towards the development of long-acting bronchodilators, which provide sustained relief from symptoms.

Local special circumstances: In the United States, the Bronchodilator Drugs market has been dominated by the use of metered-dose inhalers (MDIs). However, there has been a shift towards the use of dry powder inhalers (DPIs) in recent years. In Japan, there has been a focus on the development of new drug delivery systems, such as nebulizers, to improve patient outcomes.

Underlying macroeconomic factors: The Bronchodilator Drugs market in G20 is expected to continue growing in the coming years, driven by factors such as increasing air pollution, rising prevalence of respiratory diseases, and an aging population. However, the market may face challenges such as increasing competition from generic drugs and the high cost of some bronchodilator medications. Additionally, regulatory changes and healthcare reform efforts may impact the market in certain countries.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.